Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.28 | N/A | -56.52% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.28 | N/A | -56.52% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the recent performance but remains focused on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite current setbacks.
The earnings report indicates that United Therapeutics faced significant challenges this quarter, particularly reflected in the EPS miss. The stock reacted negatively, dropping 4.3%, likely due to investor concerns about the company's current performance and lack of guidance. Moving forward, the company will need to address these issues to regain investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 25, 2011